Acumen Pharmaceuticals (ABOS) Stock News

Acumen Pharmaceuticals (NASDAQ: ABOS) reported second quarter 2026 results and pipeline progress, including preparation for topline data from ALTITUDE-AD, its 542‑patient Phase 2 trial of sabirnetug (ACU193) in early Alzheimer’s disease, expected in late 2026. The study evaluates two IV doses (35 mg/kg, 50 mg/kg, Q4W) versus placebo over 18 months, with primary endpoint iADRS and key secondary measures including CDR-SB, ARIA rates and biomarkers.

Acumen nominated two Enhanced Brain Delivery™ candidates, ACU301 and ACU401, under its JCR license. ACU401 showed up to 40‑fold higher frontal cortex exposure and no hematological safety signals in non-human primates. An IND filing for a lead EBD clinical candidate is targeted for mid‑2027. As of June 30, 2026, cash, cash equivalents and marketable securities were $110.2 million, expected to fund operations into early 2027. Q2 2026 R&D expense declined to $27.8 million from $37.1 million a year ago, and net loss narrowed to $32.7 million from $41.0 million.

Acumen Pharmaceuticals (NASDAQ: ABOS) will report its second quarter 2026 financial results on Wednesday, August 12, 2026, and will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Participants must register in advance to receive dial-in details and PIN, while the webcast will be accessible online, with an archived version available for at least 30 days in the Investors section of Acumen’s website. The company is a clinical-stage biopharmaceutical developer of sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers in Alzheimer’s disease, now in an ongoing Phase 2 trial ALTITUDE-AD, with additional work on subcutaneous and enhanced brain delivery formulations.

Acumen Pharmaceuticals (NASDAQ: ABOS) reported new preclinical and patient-experience data from its Enhanced Brain Delivery™ (EBD™) program and ALTITUDE-AD Phase 2 trial at AAIC® 2026 in London. In collaboration with JCR Pharmaceuticals, bispecific antibodies targeting both soluble amyloid beta oligomers (AβOs) and human transferrin receptor (hTfR) showed substantially improved brain penetration in mouse and non-human primate models.

EBD candidate ACU401 achieved up to 40-fold higher frontal cortex exposure versus ACU234 in cynomolgus monkeys, with similar increases in hippocampus and putamen and no hematological findings suggestive of anemia. Semi-structured interviews from 38 ALTITUDE-AD participants and partners highlighted pervasive memory challenges, emotional burden, social withdrawal, and coping strategies, underscoring the importance of directly capturing patient experience in early Alzheimer’s disease.

Acumen Pharmaceuticals (NASDAQ: ABOS) will present three studies at AAIC 2026 in London from July 12-15, 2026. One oral and two poster presentations will cover Enhanced Brain Delivery (EBD) bispecific antibodies using transferrin-receptor targeting and patient-perspective insights from the ALTITUDE-AD early symptomatic Alzheimer’s disease trial population.

JCR Pharmaceuticals (TSE:4552) and Acumen Pharmaceuticals (NASDAQ: ABOS) expanded their Alzheimer’s collaboration as Acumen exercised its exclusive option to develop, manufacture and commercialize up to two blood-brain barrier-penetrating candidates enabled by J-Brain Cargo®.

Acumen targets an IND filing in mid-2027. JCR receives an option payment and may earn up to USD 555 million in development and sales milestones plus tiered royalties. Non-clinical mouse data showed increased brain exposure while preserving AβO selectivity, and J-Brain Cargo® is clinically validated via IZCARGO™. The impact is already reflected in JCR’s fiscal 2027 earnings forecast.

Acumen Pharmaceuticals (NASDAQ: ABOS) nominated two Enhanced Brain Delivery™ (EBD™) development candidates, ACU301 and ACU401, for Alzheimer’s disease, exercising its option under a license with JCR Pharmaceuticals.

Candidates combine Acumen’s AβO-selective antibodies with JCR’s J-Brain Cargo® to enhance blood-brain barrier penetration; IND-enabling work is underway targeting mid-2027 IND submissions.

Acumen Pharmaceuticals (NASDAQ: ABOS) reported first quarter 2026 results and Alzheimer’s pipeline updates. Cash, cash equivalents and marketable securities were $128.4 million as of Mar. 31, 2026, supported by a $35.75 million private placement, funding operations into early 2027.

R&D expenses were $16.5 million versus $25.3 million a year ago; G&A was $4.7 million versus $5.1 million. Net loss was $20.7 million, improved from $28.8 million. Topline Phase 2 ALTITUDE-AD results for sabirnetug in early Alzheimer’s are expected in late 2026, with an EBD program IND targeted for mid-2027.

Acumen Pharmaceuticals (NASDAQ: ABOS) announced management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026 at 8:55 a.m. PT / 11:55 a.m. ET.

The session will be webcast live and archived for 90 days under the Investors tab at the company website.

Acumen Pharmaceuticals (NASDAQ: ABOS) will report first quarter 2026 financial results on Tuesday, May 12, 2026. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Investors must register in advance to receive dial-in numbers and PIN; the webcast and an archived audio recording will be available on the company's Investors website for at least 30 days.